These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 25150214)
1. Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? van Roosmalen IA; Quax WJ; Kruyt FA Biochem Pharmacol; 2014 Oct; 91(4):447-56. PubMed ID: 25150214 [TBL] [Abstract][Full Text] [Related]
2. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
3. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity. Guillaume YC; Lethier L; André C J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195 [TBL] [Abstract][Full Text] [Related]
4. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956 [TBL] [Abstract][Full Text] [Related]
5. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours. Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239 [TBL] [Abstract][Full Text] [Related]
6. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Koornstra JJ; Jalving M; Rijcken FE; Westra J; Zwart N; Hollema H; de Vries EG; Hofstra RW; Plukker JT; de Jong S; Kleibeuker JH Eur J Cancer; 2005 May; 41(8):1195-202. PubMed ID: 15911244 [TBL] [Abstract][Full Text] [Related]
7. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604 [TBL] [Abstract][Full Text] [Related]
8. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X; Kandasamy K; Srivastava RK Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723 [TBL] [Abstract][Full Text] [Related]
12. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. Koornstra JJ; Kleibeuker JH; van Geelen CM; Rijcken FE; Hollema H; de Vries EG; de Jong S J Pathol; 2003 Jul; 200(3):327-35. PubMed ID: 12845629 [TBL] [Abstract][Full Text] [Related]
13. TRAIL death receptors and cancer therapeutics. Huang Y; Sheikh MS Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413 [TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Wu GS; Burns TF; Zhan Y; Alnemri ES; El-Deiry WS Cancer Res; 1999 Jun; 59(12):2770-5. PubMed ID: 10383128 [TBL] [Abstract][Full Text] [Related]
15. IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression. Tanaka F; Kawakami A; Tamai M; Nakamura H; Iwanaga N; Izumi Y; Arima K; Aratake K; Huang M; Kamachi M; Ida H; Origuchi T; Eguchi K Int J Mol Med; 2005 May; 15(5):833-9. PubMed ID: 15806306 [TBL] [Abstract][Full Text] [Related]
16. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630 [TBL] [Abstract][Full Text] [Related]
17. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
18. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128 [TBL] [Abstract][Full Text] [Related]
19. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Zhang Y; Zhang B Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831 [TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]